ERBB2 and gastroesophageal junction adenocarcinoma: This phase II trial evaluated the efficacy and safety of the combination of FOLFOX and nab-paclitaxel as first-line therapy for patients diagnosed with advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma.